DOC Updates
by American Diabetes Association
Is this your podcast?On the show
From 19 epsHosts
Recent guests
Recent episodes
T2D & Bone Density, Microarchitecture, & Strength; Early Weight Loss, Glucose Tolerance, & Long-Term Mortality/CVD Risk; and more!
Sep 24, 2026
32m 44s
Sarcopenic Obesity & T2D, Cumulative BMI Burden From Childhood to Adulthood & Risk of Metabolic Multimorbidity, and more!
Sep 14, 2026
24m 37s
Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone
Sep 8, 2026
39m 38s
Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Sep 3, 2026
22m 38s
Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance
Aug 24, 2026
32m 04s
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 24 chart positions in 24 markets.
By chart position
- 🇺🇸US · Medicine#1945K to 30K
- 🇦🇺AU · Medicine#2005K to 30K
- 🇲🇽MX · Medicine#9010K to 30K
- 🇮🇹IT · Medicine#1181K to 10K
- 🇮🇳IN · Medicine#1231K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
97K to 339K🎙 ~2x weekly·100 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
194K to 678K🇰🇪44%🇮🇸15%🇺🇸4%+21 more - Active Followers
Loyal subscribers who consistently listen
107K to 373K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 9/24/26 | T2D & Bone Density, Microarchitecture, & Strength; Early Weight Loss, Glucose Tolerance, & Long-Term Mortality/CVD Risk; and more! | Welcome to the latest episode (October 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Zoungas et al; Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. New England Journal of Medicine, 28 August 2026; doi.org/10.1056/NEJMoa2607314 Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD), press release N. Kruger, et al; Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study. BMJ 2026; 394 doi.org/10.1136/bmj-2026-100011 Dufour, et al; Type 2 Diabetes and Longitudinal Changes in Cortical and Trabecular Bone Density, Microarchitecture, and Strength: The Framingham Study. Diabetes Care 2026; dc260846. doi.org/10.2337/dc26-0846 He, et al; Early Weight Loss in Impaired Glucose Tolerance Is Associated With Reduced Long-term Mortality and Cardiovascular Risk: The Da Qing Diabetes Prevention Outcome Study. Diabetes Care 2026; dc260689. doi.org/10.2337/dc26-0689 Leavens ELS, Pebley K, Smith TT, et al; Nicotine E-Cigarettes for Cigarette Smoking Cessation: Recommendations to US-Based Clinicians. JAMA. 2026;336(9):783–790. doi.org/10.1001/jama.2026.13087 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here. | 32m 44s | ||||||
| 9/14/26 |  Sarcopenic Obesity & T2D, Cumulative BMI Burden From Childhood to Adulthood & Risk of Metabolic Multimorbidity, and more! | Welcome to the latest episode (September 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Diaz KM, Murdock ME, Serafini MA, et al. Evaluating movement breaks as a public health strategy to mitigate the harms of prolonged sitting: a large-scale pragmatic intervention. British Journal of Sports Medicine 2026;60:1208-1217. Chorniy, et al. Progression to Diabetes by Adults With Prediabetes Who Use the National Diabetes Prevention Program: A Natural Experiment. Diabetes Care 20 August 2026; 49 (9): 1576–1584. doi.org/10.2337/dc25-2485 Harnois-Leblanc, et al. Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence. Diabetes Care 20 August 2026; 49 (9): 1645–1653. doi.org/10.2337/dc25-2975 Guan, et al. Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank. Diabetes Care 20 August 2026; 49 (9): 1663–1668. doi.org/10.2337/dc26-0797 Guo, et al. Life Course Cumulative BMI Burden From Childhood to Adulthood and Risk of Metabolic Multimorbidity: A 36-Year Prospective Cohort Study. Diabetes Care 20 August 2026; 49 (9): 1567–1575. doi.org/10.2337/dc25-2889 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here. | 24m 37s | ||||||
| 9/8/26 | hypertensionaldosterone+4 | Payal Kohli | American Diabetes AssociationSidney Kimmel Medical College+7 | — | hypertensionaldosterone+5 | AstraZeneca | 39m 38s | ||
| 9/3/26 | Metabolic DysfunctionLiver Disease+3 | Jay ShubrookSusan Kuchera | American Diabetes AssociationClinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease+2 | — | MASHMASLD+4 | Lilly | 22m 38s | ||
| 8/24/26 | weight lossweight maintenance+3 | Jamie Almondoz, MD | American Board of Obesity Medicine (ABOM)University of Texas Southwestern Medical Center+2 | — | weight maintenanceobesity+3 | Lilly | 32m 04s | ||
| 8/17/26 | chronic kidney diseasetype 1 diabetes+4 | Nihar Desai | American Diabetes AssociationChronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026+2 | — | chronic kidney diseasetype 1 diabetes+8 | Bayer | 33m 00s | ||
| 8/10/26 | SGLT2 inhibitorschronic kidney disease+4 | Katherine R. TuttleAlexander Turchin | American Diabetes AssociationDiabetes, Obesity, and CardioMetabolic CARE+2 | — | SGLT2CKD+5 | — | 35m 49s | ||
| 8/10/26 | FinerenoneAlbuminuria+5 | — | American Diabetes AssociationAnn Intern Med+2 | — | FinerenoneAlbuminuria+5 | — | 32m 19s | ||
| 8/6/26 | hypertensionhigh blood pressure+3 | Dr. Minesh Rajpal | American College of CardiologyAmerican Heart Association+1 | — | hypertensionhigh blood pressure+3 | AstraZeneca | 33m 38s | ||
| 7/30/26 | diabetes researchclinical practice+3 | Alice Cheng, MDKirk Habegger, PhD+3 | American Diabetes Association | New Orleans | diabetesresearch+5 | — | 44m 41s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/24/26 | Lipoprotein(a)cardiovascular disease+3 | Michael Wilkinson | American Heart AssociationNational Lipid Association+2 | University of California San Diego HealthSidney Kimmel Medical College+2 | Lp(a)cardiovascular risk+3 | Lilly | 34m 06s | ||
| 7/17/26 | once-weekly insulinsdiabetes management+3 | Aaron King | American Diabetes AssociationWeekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin+1 | — | once-weekly insulindiabetes+3 | Novo | 25m 40s | ||
| 7/7/26 | chronic kidney diseasetype 1 diabetes+4 | Janet McGill | American Diabetes AssociationChronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026+2 | — | CKDtype 1 diabetes+6 | Bayer | 28m 18s | ||
| 6/30/26 | CagriSemaRetatrutide+4 | — | American Diabetes AssociationEfficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study+4 | — | CagriSemaRetatrutide+6 | — | 34m 30s | ||
| 6/25/26 | cardiometabolic diseasemedications+3 | Dr. Juan Frias | American Diabetes AssociationLos Angeles Institute for Metabolic Research+2 | Thomas Jefferson University | cardiometabolic medicationsdiabetes+3 | Lilly | 25m 10s | ||
| 6/24/26 | obesity treatmenteconomic costs+4 | Timothy Dall, MSMelanie R. Jay, MD+1 | American Diabetes AssociationWeill-Cornell Medical College+4 | — | DiabetesObesity+5 | — | 29m 56s | ||
| 6/10/26 | patient portal messagesolder adults+4 | Anna KahkoskaJoshua Niznik+1 | American Diabetes AssociationQualitative Analysis of Patient Portal Messages From Older Adults With Type 2 Diabetes+1 | — | diabetespatient portal+5 | — | 38m 08s | ||
| 6/2/26 | food coloring additivestype 2 diabetes+5 | — | American Diabetes AssociationFood Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort+5 | — | type 2 diabetesfood coloring+5 | — | 38m 41s | ||
| 5/29/26 | obesity careprimary care+3 | Leigh Perreault | American Diabetes AssociationImplementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial | Sidney Kimmel Medical College, Thomas Jefferson UniversityUniversity of Colorado Denver School of Medicine, Aurora, CO | obesityweight gain+3 | Lilly | 30m 00s | ||
| 5/26/26 | ObesityCardiometabolic diseases+3 | Mikhail Kosiborod | American Diabetes AssociationAmerican Heart Association+1 | — | obesitycardiometabolic diseases+6 | AstraZeneca | 33m 31s | ||
| 5/19/26 | hypercortisolismdiabetes+3 | John Buse | American Diabetes AssociationDiabetes Care | — | hypercortisolismdiabetes+5 | Corcept | 27m 06s | ||
| 5/12/26 |  Special Edition: What's Next—Cardiovascular Risk in CKD—The Overlooked Burden | We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine. Selected references: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121 | 30m 56s | ||||||
| 5/5/26 |  Special Edition: What's Next—Once-Weekly Insulin | In the early 2000s, long-acting, once-daily insulin was approved, completely changing the experience of using insulin for people with diabetes. But science doesn't stand still. Now the FDA has approved weekly insulin. In this special episode of Diabetes Core Update, Neil Skolnik speaks with Athena Philis-Tsimikas, MD about this exciting development. This special edition of Diabetes Core Update is sponsored with support from Lilly. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Athena Philis-Tsimikas, MD, Corporate Vice President of the Scripps Whittier Diabetes Institute and Diabetes Care Line at Scripps Health in San Diego, CA | 20m 46s | ||||||
| 5/1/26 |  Associations between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy, Tirzepetide vs. Dulaglutide or Semaglutide on major cardiovascular events in T2D, and more! | Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month, they discuss: Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277 Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283 Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767 Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238 Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063 Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update. | 36m 59s | ||||||
| 4/15/26 |  Special Edition: What's Next—Emerging Technologies for People with Diabetes | In this special edition on Emerging Technologies for People with Diabetes our host, Dr. Neil Skolnik will discuss recent and future advances in technologies for people with diabetes. This special episode is supported by an independent educational grant from Seagrove Partners. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Erik Veerhoef, Founder, President and CEO of Seagrove Partners | 35m 05s | ||||||
Showing 25 of 100
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for DOC Updates
Peaked at #3 in KE, top 10 in 1 of 26 tracked markets, currently #3 in KE.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| KE | — | #3 | #3 | — |
| IS | — | #13 | #13 | — |
| CO | — | #34 | #34 | — |
| VN | — | #36 | #36 | — |
| KE | — | #48 | #48 | — |
| PE | — | #58 | #58 | — |
| AE | — | #59 | #59 | — |
| Denmark | — | #72 | #72 | — |
| IS | — | #75 | #75 | — |
| Mexico | — | #90 | #90 | — |
| SA | — | #92 | #92 | — |
| TR | — | #100 | #100 | — |
| TW | — | #104 | #104 | — |
| Italy | — | #118 | #118 | — |
| India | — | #123 | #123 | — |
| RO | — | #132 | #132 | — |
| TH | — | #141 | #141 | — |
| Brazil | — | #148 | #148 | — |
| GR | — | #165 | #165 | — |
| South Korea | — | #171 | #171 | — |
Chart Positions
26 placements across 24 markets.
Chart Positions
26 placements across 24 markets.